Announcements Trials

Browse Landscape

Phase

Status

Recruiting 2 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Ipilimumab 114 pembrolizumab 95 Nivolumab 91 aldesleukin 86 Interleukin-2 57 Cyclophosphamide 54 Dacarbazine 52 Vemurafenib 39 trametinib 37 Temozolomide 37 incomplete Freund's adjuvant 35 fludarabine phosphate 35 sargramostim 32 dabrafenib 32 fludarabine 26 Bevacizumab 26 Paclitaxel 22 MART-1 Antigen 21 Granulocyte-Macrophage Colony-Stimulating Factor 21 montanide ISA 51 20 Interferon-alpha 20 Cisplatin 20 Carboplatin 19 Sorafenib 18 Introns 17 Biopsy 17 cobimetinib 16 Radiosurgery 16 atezolizumab 15 Radiotherapy 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Melanoma × daromun × Clear all

NCT02076633 2015-05-27

Intratumoral Administration of L19IL2/L19TNF

Philogen S.p.A.

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡